Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > news

<< Previous

Bullboard Posts

Next >>

Comment by Moemoney42on Jul 27, 2021 8:43pm

133 Views

Post# 33614691

RE:RE:RE:news

Moemoney42 wrote:

mavericks2020 wrote: usually after options we have good news.

Wouldn't surprise me Mavericks.. I think things are moving rather quickly.. and rightfully so.. this kind of treatment if cleared, could be a godsend for the worlds covid issues.. far more than a simple test.. which we have plenty of those options already.. we need cures.. and treatments.. thats the real game changer..!!

Also could be why the price has been held in a range lately.. to facilitate the options pricing.. just an observation.. and my opinion..

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it